Listed

Chemed Corp: Form 10-Q for the period ended Sep 30, 2024

Filed with the SEC on Nov 1, 2024 and accepted by EDGAR at Nov 1, 2024, 09:00 ET.

Share

Management's discussion and analysis

As filed, 49,677 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended September 30, 2024 2023 Nine months ended September 30, 2024 2023
Service revenues and sales $606,181 $564,532 $1,791,294 $1,678,505
Net income $75,776 $74,958 $211,680 $182,456
Diluted EPS $5.00 $4.93 $13.88 $12.02
Adjusted net income $85,485 $80,866 $248,735 $207,701
Adjusted diluted EPS $5.64 $5.32 $16.31 $13.68
Adjusted EBITDA $122,994 $115,836 $357,505 $312,253
Adjusted EBITDA as a % of revenue 20.3% 20.5% 20.0% 18.6%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 35-37.

For the three months ended September 30, 2024, the increase in consolidated service revenues and sales was driven by a 17.3% increase at VITAS offset by a 6.9% decrease at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of a 15.5% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 140-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 64-basis points. The decrease in service revenues at Roto-Rooter was driven by a decrease in all service lines.

For the nine months ended September 30, 2024, the increase in consolidated service revenues and sales was driven by a 16.1% increase at VITAS offset by a 5.9% decrease at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of a 13.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 110-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 70-basis points. The decrease in service revenues at Roto-Rooter was driven by a decrease in all service lines.

On April 17, 2024, VITAS completed the purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc d/b/a/ Covenant Care (“Covenant”) for an aggregated purchase price of $85.0 million in cash.

The pro forma revenue and earnings for the Company for the three and nine months ended September 30, as if the Covenant acquisition made in 2024 was completed on January 1, 2023 are as follows (in thousands, except per share data):

Three months ended September 30, 2024 2023 Nine months ended September 30, 2024 2023
Service revenues and sales $606,181 $578,472 $1,808,426 $1,720,325
Net income $75,776 $76,735 $215,905 $187,786
Earnings per share $5.04 $5.09 $14.31 $12.49
Diluted earnings per share $5.00 $5.05 $14.15 $12.37

Hurricane Helene, which impacted the panhandle of Florida and other parts of the southeastern United States in late September, did not result in any significant property loss or damage to VITAS. However, as with other similar events, we did experience a slowdown in admission activity while health systems prepared for the hurricane and then dealt with the aftermath. We estimate that admissions were negatively impacted during the quarter by approximately 60-100 patients. We also believe that the Florida admission impact will be more significant in the fourth quarter with the combination of Hurricanes Helene and Milton.

VITAS continues to perform as anticipated, and we reiterate the metrics for VITAS as presented in our second quarter 2024 press release. Roto-Rooter’s revenue and resulting adjusted EBITDA and adjusted net income was softer than anticipated during the third quarter of 2024. As a result of these factors, full-year 2024 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $23.00 to $23.15. This range represents a 13.3% to 14.0% increase from Chemed’s reported adjusted earnings per diluted share of $20.30. This guidance assumes an effective corporate tax rate on adjusted earnings of 24.3% and a diluted share count of 15.22 million shares.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2023 to September 30, 2024 include the following:

A $20.5 million increase in investments of deferred compensation plans due mainly to market valuation gains. This resulted in a similar increase in the liability associated with deferred compensation plans.

A $7.7 million increase in lease right of use asset due to lease renewals. This resulted in a similar increase in the lease liability accounts.

A $4.5 million increase in identifiable intangible assets due primarily to the Covenant acquisition at VITAS.

A $81.8 million increase in goodwill due primarily to the Covenant acquisition at VITAS.

A $19.1 million decrease in accounts payable due to timing of payments.

A $3.5 million decrease in income taxes payable due to timing of payments.

A $15.2 million decline in accrued compensation due primarily to the payment of 2023 bonuses in the first quarter of 2024.

A $15.1 million decrease in other current liabilities due to payments of legal settlements at VITAS and Roto-Rooter, payments of the Retention Bonus Program implemented at VITAS and a decrease in the Medicare Cap liability at VITAS.

Net cash provided by operating activities increased $30.8 million from September 30, 2023 to September 30, 2024. The main driver is an increase in earnings of $29.2 million.

Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $50.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Commitments and Contingencies

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of September 30, 2024, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and/or term loan by an additional $250.0 million.

We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We paid the remaining balance of $21.3 million on April 28, 2023. There were no prepayment penalties associated with this repayment. This prepayment reduced the total borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.

We have issued $45.2 million in standby letters of credit as of September 30, 2024, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of September 30, 2024, we have approximately $404.8 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2024 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

Results of Operations

Three months ended September 30, 2024 versus 2023 - Consolidated Results

Our service revenues and sales for the third quarter of 2024 increased 7.4% versus services and sales revenues for the third quarter of 2023. Of this increase, a $57.7 million increase was attributable to VITAS, offset by a $16.0 million decrease at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Three months ended September 30, 2024 2023 Increase/(Decrease) Percent
Routine homecare $338,344 $287,389 17.7
General inpatient 29,923 27,818 7.6
Continuous care 25,799 22,032 17.1
Other 5,082 3,562 42.7
Subtotal 399,148 340,801 17.1
Medicare cap adjustment (2,239) (125) (1,691.2)
Room and board - net (3,336) (2,646) (26.1)
Implicit price concessions (2,167) (4,302) 49.6
Net revenue $391,406 $333,728 17.3
Roto-Rooter
Drain cleaning $56,049 $59,164 (5.3)
Plumbing 43,471 49,113 (11.5)
Excavation 53,935 56,904 (5.2)
Other 218 334 (34.7)
Subtotal - short term core 153,673 165,515 (7.2)
Water restoration 42,412 45,435 (6.7)
Independent contractors 17,698 20,509 (13.7)
Outside franchisee fees 1,454 1,457 (0.2)
Other 5,408 4,246 27.4
Gross revenue 220,645 237,162 (7.0)
Implicit price concessions (5,870) (6,358) 7.7
Net revenue 214,775 230,804 (6.9)
Total Revenues $606,181 $564,532 7.4

Days of care at VITAS during the quarters were as follows:

Three months ended September 30, 2024 2023 Increase/(Decrease) Percent
Routine homecare 1,622,680 1,391,377 16.6
Nursing home 320,664 287,785 11.4
Respite 9,952 7,292 36.5
Subtotal routine homecare and respite 1,953,296 1,686,454 15.8
General inpatient 26,524 25,493 4.0
Continuous care 24,365 23,071 5.6
Total days of care 2,004,185 1,735,018 15.5

The increase in service revenues at VITAS is comprised primarily of a 15.5% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 140-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 64-basis.

The decrease in drain cleaning revenues for the third quarter of 2024 versus 2023 is attributable to a 3.6% increase in price and service mix offset by an 8.9% decrease in job count. The decrease in plumbing revenues for the third quarter of 2024 versus 2023 is attributable to a 1.8% decrease in price and service mix shift and a 9.7% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues.

The consolidated gross margin was 34.6% in the third quarter of 2024 as compared with 35.8% in the third quarter of 2023. On a segment basis, VITAS’ gross margin was 24.6% in the third quarter of 2024 as compared with 24.0%, in the third quarter of 2023. The increase in gross margin at VITAS is mostly the result of increased revenues. The Roto-Rooter segment’s gross margin was 52.9% for the third quarter of 2024 and the third quarter of 2023.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended September 30, 2024 2023
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $93,269 $91,792
Impact of market value adjustments related to assets held in deferred compensation trusts 5,629 4,257
Long-term incentive compensation 3,083 3,553
Total SG&A expenses $101,981 $99,602

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the third quarter of 2024 were up 1.6% when compared to third quarter of 2023 due mainly to normal salary increases and an increase in variable selling expenses, primarily increased marketing expense at Roto-Rooter.

Other income – net comprise (in thousands):

Three months ended September 30, 2024 2023
Market value adjustment on assets held in deferred compensation trusts $5,629 $4,257
Interest income 3,668 2,600
Other 2 2
Total other income - net $9,299 $6,859

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. In 2023, Chemed began investing excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended September 30, 2024 2023
Income tax provision calculated at the statutory federal rate $21,216 $19,586
State and local income taxes 2,857 2,105
Stock compensation tax benefits (389) (225)
Effect of rate change on deferred tax - (4,241)
Other--net 1,569 1,082
Income tax provision $25,253 $18,307
Effective tax rate 25.0% 19.6%

During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating resources and profitability by business segment. This benefit includes a reduction in current state and local tax expense and a one time benefit of $4.2 million in reduction of deferred tax liabilities reflecting the lower tax rates.

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Three months ended September 30, 2024 2023
Acquisition expense $(298) $-
Impact of deferred rate tax change - 1,772
Roto-Rooter
Amortization of reacquired franchise agreements (1,804) (1,954)
Acquisition expense 6 -
Impact of deferred rate tax change - 3,559
Litigation settlements - (286)
Corporate
Stock option expense (5,240) (4,924)
Long-term incentive compensation (2,762) (3,210)
Excess tax benefits on stock compensation 389 225
Impact of deferred rate tax change - (1,090)
Total $(9,709) $(5,908)

Three months ended September 30, 2024 versus 2023 - Segment Results

Net income/(loss) for the third quarter of 2024 versus the third quarter of 2023 by segment (in thousands):

Three months ended September 30, 2024 2023
VITAS $53,486 $44,331
Roto-Rooter 37,955 50,327
Corporate (15,665) (19,700)
$75,776 $74,958

After-tax earnings as a percent of revenue at VITAS in the third quarter of 2024 was 13.7% as compared to 13.3% in the third quarter of 2023. VITAS’ after-tax earnings increased primarily due to increased revenues.

Roto-Rooter’s net income was negatively impacted in the third quarter of 2024 compared to the third quarter of 2023 primarily due to declining revenue and higher SG&A related to enhanced marketing efforts. After-tax earnings as a percent of revenue at Roto-Rooter in the third quarter of 2024 was 17.7%, as compared to 21.8% in the third quarter of 2023.

After-tax Corporate expenses for the third quarter of 2024 decreased 20.5% when compared to the third quarter in 2023 due primarily to the tax benefit from the realignment of state and local corporate tax structure change recognized in September 2023, and market gains and interest income from excess cash invested in money market funds.

Results of Operations

Nine months ended September 30, 2024 versus 2023 - Consolidated Results

Our service revenues and sales for the first nine months of 2024 increased 6.7% versus services and sales revenues for the first nine months of 2023. Of this increase, a $154.9 million increase was attributable to VITAS, offset by a $42.1 million decrease at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Nine months ended September 30, 2024 2023 Increase/(Decrease) Percent
Routine homecare $967,981 $832,554 16.3
General inpatient 89,297 84,312 5.9
Continuous care 74,295 63,054 17.8
Other 13,900 9,738 42.7
Subtotal 1,145,473 989,658 15.7
Medicare cap adjustment (5,989) (5,625) (6.5)
Room and board - net (9,437) (8,317) (13.5)
Implicit price concessions (10,077) (10,650) 5.4
Net revenue $1,119,970 $965,066 16.1
Roto-Rooter
Drain cleaning $175,535 $186,016 (5.6)
Plumbing 137,614 148,285 (7.2)
Excavation 168,266 174,032 (3.3)
Other 665 711 (6.5)
Subtotal - short term core 482,080 509,044 (5.3)
Water restoration 131,867 141,176 (6.6)
Independent contractors 55,569 65,684 (15.4)
Outside franchisee fees 4,344 4,195 3.6
Other 17,287 13,292 30.1
Gross revenue 691,147 733,391 (5.8)
Implicit price concessions (19,823) (19,952) 0.6
Net revenue 671,324 713,439 (5.9)
Total Revenues $1,791,294 $1,678,505 6.7

Days of care at VITAS during the nine months ended September 30 were as follows:

Nine months ended September 30, 2024 2023 Increase/(Decrease) Percent
Routine homecare 4,621,755 4,018,469 15.0
Nursing home 908,013 833,112 9.0
Respite 26,806 19,211 39.5
Subtotal routine homecare and respite 5,556,574 4,870,792 14.1
General inpatient 79,064 76,987 2.7
Continuous care 72,335 65,630 10.2
Total days of care 5,707,973 5,013,409 13.9

The increase in service revenues at VITAS is comprised primarily of a 13.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 110-basis points when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 70-basis points.

The decrease in drain cleaning revenues for the first nine months of 2024 versus 2023 is attributable to a 2.6% increase in price and service mix offset by an 8.2% decrease in job count. The decrease in plumbing revenues for the first nine months of 2024 versus 2023 is attributable to a 1.2% decrease in price and service mix shift and by a 6.0% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues.

The consolidated gross margin was 34.6% in the first nine months of 2024 as compared with 34.0% in the first nine months of 2023. On a segment basis, VITAS’ gross margin was 23.9% in the first nine months of 2024 as compared with 20.2%, in the first nine months of 2023. The increase in gross margin at VITAS is mostly the result of increased revenues and the expiration of the licensed healthcare worker Retention Bonus Program in 2023. The expense recorded in the first nine months of 2023 related to the VITAS Retention Bonus Program was $23.8 million. The Roto-Rooter segment’s gross margin was 52.5% for the first nine months of 2024 as compared with 52.8% in the first nine months of 2023.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Nine months ended September 30, 2024 2023
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $287,712 $281,426
Impact of market value adjustments related to assets held in deferred compensation trusts 16,600 5,441
Long-term incentive compensation 15,797 7,817
Total SG&A expenses $320,109 $294,684

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first nine months of 2024 were up 2.2% when compared to the first nine months of 2023 due mainly to normal salary increases and an increase in variable selling expenses, primarily increased marketing expense at Roto-Rooter.

Other income – net comprise (in thousands):

Nine months ended September 30, 2024 2023
Market value adjustment on assets held in deferred compensation trusts $16,600 $5,441
Interest income 11,405 2,863
Other 3 61
Total other income - net $28,008 $8,365

Our effective tax rate reconciliation is as follows (in thousands):

Nine months ended September 30, 2024 2023
Income tax provision calculated at the statutory federal rate $58,662 $49,303
State and local income taxes 8,279 7,333
Stock compensation tax benefits (4,308) (3,376)
Effect of rate change on deferred tax - (4,241)
Other--net 5,029 3,299
Income tax provision $67,662 $52,318
Effective tax rate 24.2% 22.3%

During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating resources and profitability by business segment. This benefit includes a reduction in current state and local tax expense and a one time benefit of $4.2 million in reduction of deferred tax liabilities reflecting the lower tax rates.

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Nine months ended September 30, 2024 2023
Acquisition expense $(985) $-
Impact of deferred rate tax change - 1,772
Roto-Rooter
Amortization of reacquired franchise agreements (5,412) (5,412)
Acquisition expense (29) -
Impact of deferred rate tax change - 3,559
Litigation settlements - (1,577)
Corporate
Stock option expense (20,203) (18,884)
Long-term incentive compensation (9,397) (6,989)
Severance arrangement (5,337) -
Excess tax benefits on stock compensation 4,308 3,376
Impact of deferred rate tax change - (1,090)
Total $(37,055) $(25,245)

Nine months ended September 30, 2024 versus 2023 - Segment Results

Net income/(loss) for the first nine months of 2024 versus the first nine months of 2023 by segment (in thousands):

Nine months ended September 30, 2024 2023
VITAS $146,707 $95,223
Roto-Rooter 119,326 142,354
Corporate (54,353) (55,121)
$211,680 $182,456

After-tax earnings as a percent of revenue at VITAS in the first nine months of 2024 was 13.1% as compared to 9.9% in the first nine months of 2023. VITAS’ after-tax earnings increased primarily due to increased revenues and the expiration of the licensed healthcare worker Retention Bonus Program in 2023.

Roto-Rooter’s net income was negatively impacted in the first nine months of 2024 compared to the first nine months of 2023 primarily due to declining revenue and higher SG&A related to enhanced marketing efforts. After-tax earnings as a percent of revenue at Roto-Rooter in the first nine months of 2024 was 17.8%, as compared to 20.0% in the first nine months of 2023.

After-tax Corporate expenses for the first nine months of 2024 decreased by 1.4% compared to the first nine months in 2023 primarily due to the tax benefit from the realignment of state and local corporate tax structure change recognized in September 2023.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024

(in thousands)(unaudited)

2024 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $391,406 $214,775 $- $606,181
Cost of services provided and goods sold 294,936 101,251 - 396,187
Selling, general and administrative expenses 25,883 57,072 19,026 101,981
Depreciation 5,063 8,071 13 13,147
Amortization 26 2,524 - 2,550
Other operating expense 97 62 - 159
Total costs and expenses 326,005 168,980 19,039 514,024
Income/(loss) from operations 65,401 45,795 (19,039) 92,157
Interest expense (46) (114) (267) (427)
Intercompany interest income/(expense) 4,920 3,656 (8,576) -
Other income—net 62 18 9,219 9,299
Income/(expense) before income taxes 70,337 49,355 (18,663) 101,029
Income taxes (16,851) (11,400) 2,998 (25,253)
Net income/(loss) $53,486 $37,955 $(15,665) $75,776
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(6,038) $(6,038)
Long-term incentive compensation - - (3,083) (3,083)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Acquisition expense (394) 8 - (386)
Total $(394) $(2,344) $(9,121) $(11,859)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(5,240) $(5,240)
Long-term incentive compensation - - (2,762) (2,762)
Amortization of reacquired franchise agreements - (1,804) - (1,804)
Acquisition expense (298) 6 - (292)
Excess tax benefits on stock compensation - - 389 389
Total $(298) $(1,798) $(7,613) $(9,709)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023

(in thousands)(unaudited)

2023 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $333,728 $230,804 $- $564,532
Cost of services provided and goods sold 253,731 108,627 - 362,358
Selling, general and administrative expenses 25,256 55,141 19,205 99,602
Depreciation 5,009 7,836 13 12,858
Amortization 26 2,495 - 2,521
Other operating expense/(income) (53) 396 - 343
Total costs and expenses 283,969 174,495 19,218 477,682
Income/(loss) from operations 49,759 56,309 (19,218) 86,850
Interest expense (52) (131) (261) (444)
Intercompany interest income/(expense) 4,935 3,040 (7,975) -
Other income—net 849 34 5,976 6,859
Income/(expense) before income taxes 55,491 59,252 (21,478) 93,265
Income taxes (11,160) (8,925) 1,778 (18,307)
Net income/(loss) $44,331 $50,327 $(19,700) $74,958
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(5,495) $(5,495)
Long-term incentive compensation - - (3,553) (3,553)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Litigation settlements - (300) - (300)
Total $- $(2,652) $(9,048) $(11,700)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(4,924) $(4,924)
Impact of deffered rate tax change 1,772 3,559 (1,090) 4,241
Long-term incentive compensation - - (3,210) (3,210)
Amortization of reacquired franchise agreements - (1,954) - (1,954)
Litigation settlements - (286) - (286)
Excess tax benefits on stock compensation - - 225 225
Total $1,772 $1,319 $(8,999) $(5,908)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024

(in thousands)(unaudited)

2024 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $1,119,970 $671,324 $- $1,791,294
Cost of services provided and goods sold 852,347 318,717 - 1,171,064
Selling, general and administrative expenses 73,968 175,683 70,458 320,109
Depreciation 15,288 24,275 38 39,601
Amortization 79 7,538 - 7,617
Other operating expense 160 128 - 288
Total costs and expenses 941,842 526,341 70,496 1,538,679
Income/(loss) from operations 178,128 144,983 (70,496) 252,615
Interest expense (138) (349) (794) (1,281)
Intercompany interest income/(expense) 15,096 10,638 (25,734) -
Other income—net 138 64 27,806 28,008
Income/(expense) before income taxes 193,224 155,336 (69,218) 279,342
Income taxes (46,517) (36,010) 14,865 (67,662)
Net income/(loss) $146,707 $119,326 $(54,353) $211,680
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(23,933) $(23,933)
Long-term incentive compensation - - (10,460) (10,460)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Severance arrangement - - (5,337) (5,337)
Acquisition expense (1,302) (37) - (1,339)
Total $(1,302) $(7,093) $(39,730) $(48,125)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(20,203) $(20,203)
Long-term incentive compensation - - (9,397) (9,397)
Amortization of reacquired franchise agreements - (5,412) - (5,412)
Severance arrangement - - (5,337) (5,337)
Acquisition expense (985) (29) - (1,014)
Excess tax benefits on stock compensation - - 4,308 4,308
Total $(985) $(5,441) $(30,629) $(37,055)

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

(in thousands)(unaudited)

2023 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $965,066 $713,439 $- $1,678,505
Cost of services provided and goods sold 770,470 336,786 - 1,107,256
Selling, general and administrative expenses 71,248 171,966 51,470 294,684
Depreciation 14,907 22,830 41 37,778
Amortization 78 7,470 - 7,548
Other operating expense/(income) (15) 2,079 - 2,064
Total costs and expenses 856,688 541,131 51,511 1,449,330
Income/(loss) from operations 108,378 172,308 (51,511) 229,175
Interest expense (154) (387) (2,225) (2,766)
Intercompany interest income/(expense) 14,393 8,652 (23,045) -
Other income - net 1,109 96 7,160 8,365
Income/(expense) before income taxes 123,726 180,669 (69,621) 234,774
Income taxes (28,503) (38,315) 14,500 (52,318)
Net income/(loss) $95,223 $142,354 $(55,121) $182,456
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(22,376) $(22,376)
Long-term incentive compensation - - (7,817) (7,817)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Litigation settlements - (2,056) - (2,056)
Total $- $(9,112) $(30,193) $(39,305)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(18,884) $(18,884)
Long-term incentive compensation - - (6,989) (6,989)
Amortization of reacquired franchise agreements - (5,412) - (5,412)
Impact of deferred rate tax change 1,772 3,559 (1,090) 4,241
Litigation settlements - (1,577) - (1,577)
Excess tax benefits on stock compensation - - 3,376 3,376
Total $1,772 $(3,430) $(23,587) $(25,245)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the three months ended September 30, 2024 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $53,486 $37,955 $(15,665) $75,776
Add/(deduct):
Interest expense 46 114 267 427
Income taxes 16,851 11,400 (2,998) 25,253
Depreciation 5,063 8,071 13 13,147
Amortization 26 2,524 - 2,550
EBITDA 75,472 60,064 (18,383) 117,153
Add/(deduct):
Intercompany interest expense/(income) (4,920) (3,656) 8,576 -
Interest income (59) (18) (3,589) (3,666)
Stock option expense - - 6,038 6,038
Long-term incentive compensation - - 3,083 3,083
Acquisition Expense 394 (8) - 386
Adjusted EBITDA $70,887 $56,382 $(4,275) $122,994
Chemed
For the three months ended September 30, 2023 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $44,331 $50,327 $(19,700) $74,958
Add/(deduct):
Interest expense 52 131 261 444
Income taxes 11,160 8,925 (1,778) 18,307
Depreciation 5,009 7,836 13 12,858
Amortization 26 2,495 - 2,521
EBITDA 60,578 69,714 (21,204) 109,088
Add/(deduct):
Intercompany interest expense/(income) (4,935) (3,040) 7,975 -
Interest income (847) (34) (1,719) (2,600)
Stock option expense - - 5,495 5,495
Long-term incentive compensation - - 3,553 3,553
Litigation settlements - 300 - 300
Adjusted EBITDA $54,796 $66,940 $(5,900) $115,836

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the nine months ended September 30, 2024 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $146,707 $119,326 $(54,353) $211,680
Add/(deduct):
Interest expense 138 349 794 1,281
Income taxes 46,517 36,010 (14,865) 67,662
Depreciation 15,288 24,275 38 39,601
Amortization 79 7,538 - 7,617
EBITDA 208,729 187,498 (68,386) 327,841
Add/(deduct):
Intercompany interest expense/(income) (15,096) (10,638) 25,734 -
Interest income (136) (64) (11,205) (11,405)
Stock option expense - - 23,933 23,933
Long-term incentive compensation - - 10,460 10,460
Severance arrangement - - 5,337 5,337
Acquisition expense 1,302 37 - 1,339
Adjusted EBITDA $194,799 $176,833 $(14,127) $357,505
Chemed
For the nine months ended September 30, 2023 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $95,223 $142,354 $(55,121) $182,456
Add/(deduct):
Interest expense 154 387 2,225 2,766
Income taxes 28,503 38,315 (14,500) 52,318
Depreciation 14,907 22,830 41 37,778
Amortization 78 7,470 - 7,548
EBITDA 138,865 211,356 (67,355) 282,866
Add/(deduct):
Intercompany interest expense/(income) (14,393) (8,652) 23,045 -
Interest income (1,046) (96) (1,720) (2,862)
Stock option expense - - 22,376 22,376
Long-term incentive compensation - - 7,817 7,817
Litigation settlements - 2,056 - 2,056
Adjusted EBITDA $123,426 $204,664 $(15,837) $312,253

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023
Net income as reported $75,776 $74,958 $211,680 $182,456
Add/(deduct) pre-tax cost of:
Stock option expense 6,038 5,495 23,933 22,376
Long-term incentive compensation 3,083 3,553 10,460 7,817
Amortization of reacquired franchise agreements 2,352 2,352 7,056 7,056
Severance arrangement - - 5,337 -
Acquisition expense 386 - 1,339 -
Litigation settlements - 300 - 2,056
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (1,761) (1,326) (6,762) (6,443)
Tax impact of deferred tax rate change - (4,241) - (4,241)
Excess tax benefits on stock compensation (389) (225) (4,308) (3,376)
Adjusted net income $85,485 $80,866 $248,735 $207,701
Diluted Earnings Per Share As Reported
Net income $5.00 $4.93 $13.88 $12.02
Average number of shares outstanding 15,168 15,200 15,253 15,178
Adjusted Diluted Earnings Per Share
Adjusted net income $5.64 $5.32 $16.31 $13.68
Adjusted average number of shares outstanding 15,168 15,200 15,253 15,178
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

OPERATING STATISTICS Net revenue ($000) Three Months Ended September 30, 2024 2023 Nine Months Ended September 30, 2024 2023
Homecare $338,344 $287,389 $967,981 $832,554
Inpatient 29,923 27,818 89,297 84,312
Continuous care 25,799 22,032 74,295 63,054
Other 5,082 3,562 13,900 9,738
Subtotal $399,148 $340,801 $1,145,473 $989,658
Room and board, net (3,336) (2,646) (9,437) (8,317)
Contractual allowances (2,167) (4,302) (10,077) (10,650)
Medicare cap allowance (2,239) (125) (5,989) (5,625)
Total $391,406 $333,728 $1,119,970 $965,066
Net revenue as a percent of total before Medicare cap allowances
Homecare 84.8% 84.3% 84.5% 84.1%
Inpatient 7.5 8.2 7.8 8.5
Continuous care 6.5 6.5 6.5 6.4
Other 1.2 1.0 1.2 1.0
Subtotal 100.0 100.0 100.0 100.0
Room and board, net (0.8) (0.8) (0.8) (0.8)
Contractual allowances (0.5) (1.3) (0.9) (1.1)
Medicare cap allowance (0.6) - (0.5) (0.6)
Total 98.1% 97.9% 97.8% 97.5%
Days of care
Homecare 1,622,680 1,391,377 4,621,755 4,018,469
Nursing home 320,664 287,785 908,013 833,112
Respite 9,952 7,292 26,806 19,211
Subtotal routine homecare and respite 1,953,296 1,686,454 5,556,574 4,870,792
Inpatient 26,524 25,493 79,064 76,987
Continuous care 24,365 23,071 72,335 65,630
Total 2,004,185 1,735,018 5,707,973 5,013,409
Number of days in relevant time period 92 92 274 273
Average daily census (days)
Homecare 17,639 15,124 16,867 14,720
Nursing home 3,485 3,128 3,314 3,052
Respite 108 79 98 70
Subtotal routine homecare and respite 21,232 18,331 20,279 17,842
Inpatient 288 277 289 282
Continuous care 265 251 264 240
Total 21,785 18,859 20,832 18,364
Total Admissions 16,775 15,774 51,020 47,564
Total Discharges 16,217 15,328 48,285 45,837
Average length of stay (days) 102.0 103.1 102.2 100.8
Median length of stay (days) 18.0 17.0 17.0 16.0
ADC by major diagnosis
Cerebro 43.6% 42.0% 43.7% 42.2%
Neurological 13.3 14.7 13.3 15.9
Cancer 10.0 10.6 10.0 10.6
Cardio 16.3 16.4 16.2 16.1
Respiratory 7.1 7.2 7.2 7.1
Other 9.7 9.1 9.6 8.1
Total 100.0% 100.0% 100.0% 100.0%
Admissions by major diagnosis
Cerebro 28.4% 26.6% 27.7% 26.3%
Neurological 7.7 8.8 7.9 9.9
Cancer 25.7 26.1 25.1 26.0
Cardio 15.1 16.0 15.7 16.2
Respiratory 9.5 9.7 9.9 10.1
Other 13.6 12.8 13.7 11.5
Total 100.0% 100.0% 100.0% 100.0%
Estimated uncollectible accounts as a percent of revenues 1.0% 1.3% 0.9% 1.1%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 37.5 36.4 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments 35.5 33.8 n.a. n.a.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Market risk

As filed, 576 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2024, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Controls and procedures

As filed, 845 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 2,077 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

On October 4, 2024, CMS released a memo outlining the hospice Special Focus Program (“SFP”) criteria, and announcing that in November 2024, they would select the 50 hospices for participation in the SFP during the next calendar year.

As we disclosed in our Annual Report on form 10-K, filed February 29,2024, the SFP is intended to identify “poor performing” hospices based on a number of indicators. Under an algorithm that it has developed for the SFP, CMS will identify the bottom 10% of performers and provide additional oversight over the lowest 1% of performers to assist the programs with “continuous improvement.” It is possible that certain VITAS hospice locations are included in the hospices that the algorithm identifies within the bottom 10% or even bottom 1% of hospices, and therefore selected for the SFP. Although CMS has stated that providers will not be able to replicate the results of the algorithm because not all information utilized by CMS has been made public, given what is known, large providers appear to be significantly more likely to be identified as poor performers because the formula does not account for size of program when analyzing the number of substantiated complaints. Additionally, providers who submit Consumer Assessment of Healthcare Providers and Systems (“CAHPS”) scores (as VITAS does) appear to be more likely to be identified as poor performers.

Although there are no direct financial fines, fees, or other penalties or operational changes imposed due to selection in the SFP, the selection of one or more of VITAS programs in the SFP could have a material adverse effect on VITAS due to adverse effects on VITAS’ brand reputation and patient referral patterns. Additionally, participation in the SFP could materially increase costs of regulatory compliance for the programs selected to participate in the SFP due to additional government oversight and intervention in that program.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2024-07-01 to 2024-09-30$391.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2024-01-01 to 2024-09-30$1.12bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2024-07-01 to 2024-09-30$396.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2024-01-01 to 2024-09-30$1.17bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2024-07-01 to 2024-09-30$102.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2024-01-01 to 2024-09-30$320.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2024-07-01 to 2024-09-30$92.2mus-gaap:OperatingIncomeLoss
Operating income9 months2024-01-01 to 2024-09-30$252.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2024-07-01 to 2024-09-30$427.0kus-gaap:InterestExpense
Interest expense9 months2024-01-01 to 2024-09-30$1.3mus-gaap:InterestExpense
Income tax3 months2024-07-01 to 2024-09-30$25.3mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2024-01-01 to 2024-09-30$67.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2024-07-01 to 2024-09-30$75.8mus-gaap:NetIncomeLoss
Net income9 months2024-01-01 to 2024-09-30$211.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2024-07-01 to 2024-09-30$5.00us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2024-01-01 to 2024-09-30$13.88us-gaap:EarningsPerShareDiluted
Basic EPS3 months2024-07-01 to 2024-09-30$5.04us-gaap:EarningsPerShareBasic
Basic EPS9 months2024-01-01 to 2024-09-30$14.04us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2024-07-01 to 2024-09-3015,168,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2024-01-01 to 2024-09-3015,253,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2024-01-01 to 2024-09-30$252.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2024-01-01 to 2024-09-30$36.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2024-01-01 to 2024-09-30$19.6mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2024-01-01 to 2024-09-30$152.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2024-09-30$238.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2024-09-30$490.4mus-gaap:AssetsCurrent
Total assetsAt period end2024-09-30$1.77bnus-gaap:Assets
Current liabilitiesAt period end2024-09-30$264.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2024-09-30$533.7mus-gaap:Liabilities
Shareholders' equityAt period end2024-09-30$1.24bnus-gaap:StockholdersEquity
Shares outstandingAt period end2024-09-3014,982,607 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001562762-24-000248. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.